BridgeBio says FDA accepts infigratinib NDA for achondroplasia, grants priority review
BridgeBio NDA for oral infigratinib in children with achondroplasia accepted by FDA for Priority Review. PDUFA target action date set for Feb. 4, 2027. * PROPEL 3 Phase 3 study supported filing, showing a +2.10 cm/year annualized height-velocity treatment effect. Disclaimer: This news brief was created by Public Techno